Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Kothari S, Hillengass J, McCarthy PL, Holstein SA. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter? Current Hematologic Malignancy Reports 2019, 14: 39-46. PMID: 30671912, DOI: 10.1007/s11899-019-0497-7.Peer-Reviewed Original ResearchConceptsMinimal residual diseaseProgression-free survivalOverall survivalResidual diseaseImproved progression-free survivalRecent clinical trial dataRecent phase III studyMRD-negativity ratesPhase III studyBone marrow samplesClinical trial dataClinical trial designMRD negativityMRD statusIII studyMRD assessmentTreatment armsMultiple myelomaClinical trialsNegativity ratePrognostic biomarkerTreatment decisionsMarrow samplesSurrogate endpointsTrial design
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply